Allspring Global Investments Holdings LLC Acquires 509,163 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 40.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,760,781 shares of the medical research company’s stock after purchasing an additional 509,163 shares during the period. Allspring Global Investments Holdings LLC owned about 3.42% of Charles River Laboratories International worth $346,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Czech National Bank lifted its position in shares of Charles River Laboratories International by 0.5% during the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock worth $2,445,000 after buying an additional 41 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of Charles River Laboratories International by 1.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock valued at $914,000 after acquiring an additional 45 shares during the period. American Trust boosted its stake in shares of Charles River Laboratories International by 5.9% in the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 54 shares in the last quarter. Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after purchasing an additional 57 shares during the last quarter. Finally, OLD National Bancorp IN grew its holdings in shares of Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after purchasing an additional 59 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.0 %

CRL traded down $0.01 during trading on Friday, reaching $197.77. 707,810 shares of the company’s stock were exchanged, compared to its average volume of 596,940. The company’s fifty day moving average price is $197.20 and its 200-day moving average price is $213.73. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58. The firm has a market capitalization of $10.19 billion, a PE ratio of 23.27, a P/E/G ratio of 5.11 and a beta of 1.36. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.03 billion. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International announced that its board has initiated a share repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

CRL has been the topic of a number of recent analyst reports. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their price target for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Barclays decreased their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Wednesday. Bank of America lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Finally, Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $212.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).